

of those pts showed documented tumor progression within 3 weeks of last CPT-11 therapy.

**Results: Pts characteristics:** median age 56 yrs.; PS (WHO) 0: 0 pts; PS 1: 8 pts; PS 2: 2 pts. All pts had at least 1 tumor related symptom. Median number of organs involved: 3.

**Treatment:** 4 pts received DDP 75 mg/m<sup>2</sup>dl, FU 1000 mg/m<sup>2</sup> continuous infusion (CI)d1-5,q3w; 5 pts: DDP 50 mg/m<sup>2</sup>d1, FU 2.0-2.6 g/m<sup>2</sup> Cld1 + 8, Folinic acid (FA) 500 mg/m<sup>2</sup>d1 + 8,q2w; 1 pt: DDP 120 mgdl, FA 100 mgdl-3, FU 1.5 gdl-3CI,q3w. Median number of cycles given: 3.

**Response rate:** PR: 2 pts, NC: 4 pts. After documented progression under CPT-11 the tumor control rate is 60%. Median time to tumor progression: 16 wks. Symptomatic improvement: 50%. Out of 3 pts who had PD as best response to CPT-11 (primary resistance) 1 achieved PR and 2 NC.

**Toxicity:** grade 2: mucositis 2 pts, diarrhea 1 pt. nausea and vomiting 5 pts, asthenia 3 pts; grade 3: mucositis 1 pt. grade 4: 0.

**Conclusion:** 2nd-line DDP/FU after progression while receiving CPT-11 is an active combination and results in a tumor control rate of 60% and symptomatic improvement in 50%. DDP/FU and CPT-11 show a lack of cross resistance.

552

PUBLICATION

### Continuous infusion 5-Fluorouracil with or without cisplatin for the treatment of advanced gastric cancer. Results of two consecutive phase II trials of the Spanish Group for Gastrointestinal Tumor Therapy (TTD)

A. Cervantes<sup>1</sup>, M. Navarro<sup>2</sup>, A. Carrato<sup>2</sup>, J. Sastre<sup>2</sup>, A. Anton<sup>2</sup>, Jm. Vicent<sup>2</sup>, Jm. Tabernero<sup>2</sup>, J. Aparicio<sup>2</sup>, P. Escudero<sup>2</sup>, E. Diaz-Rubio<sup>2</sup>.  
<sup>2</sup>TTD Group; <sup>1</sup>University Hospital, Hematology And Medical Oncology, Valencia, Spain

Advanced gastric cancer (AGC) has a poor outcome and chemotherapy has mainly a palliative effect. Despite many years of chemotherapy, there are no definite data to suggest that 5-FU alone is inferior to other treatment.

The TTD group carried out two consecutive phase II trials in patients with biopsy proven AGC with measurable disease, Performance Status (PS) < 3 and normal liver, kidney, heart and marrow function. In the first one 5-FU was given as a single agent in 48-hours continuous infusion (3 g/m<sup>2</sup>(sub)2/(sub)) every week. In the second trial cisplatin (3 g/m<sup>2</sup>(sub)2/(sub)) was added every 3 weeks to the same 5-FU schedule. Median age, pretreatment PS, previous surgery and median number of metastatic locations was similar for both groups. Toxicity was mild for both types of treatment. With infusional 5-FU 7% of patients suffered from CTC grade 3-4 toxicity. The addition of cisplatin induced 12% of grade 3-4 toxicity. In the first trial 89 patients were treated with 5-FU alone. Overall response rate (ORR) was 18% (10-26, CI at 95%), with 7% complete responses (CR). Time to progression (TTP) and overall survival (OS) was 4.8 and 6.9 months, respectively. In the second consecutive trial 130 patients were treated with 5-FU plus cisplatin. ORR was 47% (39-55, CI at 95%), with 4% CR. TTP and OS was 4.8 and 9.2 months, respectively. The addition of cisplatin increases significantly the proportion of responses (ORR), without affecting the complete response rate (CR). However, there are no differences in time to progression (TTP) in both treatments. Overall survival (OS) favors patients treated in the combination therapy trial. Though this is the highest survival obtained in four consecutive trials of the TTD group, the design of the study does not allow to check if this advantage is statistically significant.

553

PUBLICATION

### MRI in the long term follow up of patients treated with chemo-radiation (CRT) for anal cancer

D. Tait<sup>1</sup>, A. Dziki-Djuraz<sup>2</sup>, J. Husband<sup>2</sup>, J. Glees<sup>1</sup>, S. Essapen<sup>1</sup>, C. Abson<sup>1</sup>, S. Brooker<sup>1</sup>. <sup>1</sup>Royal Marsden Hospital, Clinical Oncology, Sutton; <sup>2</sup>Institute of Cancer Research, Academic Dept. of Radiology, Sutton, United Kingdom

**Purpose:** To assess MRI as a means of detecting early tumour recurrence and of describing the late normal tissue effects in the perianal soft tissue and femoral heads.

**Method:** 18 patients with squamous cell carcinoma of the anus, treated with chemo-radiation according to the UKCCF protocol, have had an MRI examination one year post completion of treatment. Small field of view axial and coronal T2 and STIR images were used to define the anal complex anatomically. Perianal distortion was scored nil to marked (0-3) and the presence of avascular necrosis (AVN) of the femoral heads documented.

**Results:** There has been no clinical evidence of recurrent disease as determined by clinical and endoscopic examination. The MR criterion taken to indicate local disease control was the absence of a focus of high signal intensity in T2 and STIR imaging, greater than 1 cm in size. No such foci were detected. The most striking feature in all cases was the low signal intensity of the anal and peri-anal complex. This low signal intensity is in keeping with a short T2 characteristic of fibrosis. This appearance was scored 1 in 9 patients (50%), 2 in 5 patients (28%) and 3 in 3 patients (16%). One patient was unable to tolerate the MR examination. No cases of AVN were seen.

**Conclusion:** By the given MR criteria, MR supported the clinical and endoscopic impression of local tumour control. No MR evidence of femoral head AVN was seen in this sample of patients. MR has highlighted the varying degrees of architectural distortion of the anal complex at one year post chemo-radiation. This discriminating morphological scoring of these changes will permit correlation with functional outcome. Yearly examination are ongoing for this purpose.

554

PUBLICATION

### Quality of life as outcome parameter in gastrointestinal (GI) surgery EORTC-QLQ-C-30 and tumor specific modules

Ch. Schmidt<sup>1</sup>, F. Reibe<sup>1</sup>, T. Küchler<sup>2</sup>, B. Kremer<sup>1</sup>. <sup>1</sup>CAU Kiel, Allgemeine und Thoraxchirurgie, Kiel; <sup>2</sup>CAU Kiel, Referenzzentrum Lebensqualität in der Onkologie, Kiel, Germany

Quality of Life (QoL) has become an important issue in modern quality management to measure health outcome in tumor surgery. Since September 1998 patients with GI tumors have been assessed pre- and postoperatively for their health related Quality of Life in daily clinical routine in our department. Development of the QoL modules used in this trial takes time and is depending on specific guidelines given by the EORTC.

From 1987-89 in a prospective prestudy QoL in 74 patients with GI tumors was measured at the Dep. of surgery at the University hospital of Hamburg. In open interviews patients were asked for symptoms before, during and after therapy. This list of symptoms was completed by consulting experts and literature review. All subjectively experienced symptoms were worded into simple questions and tested for clarity. These modules were used in two main studies with 500 (300 + 200) patients from 1990-96. Patients answered the questionnaires one day before surgery (Z0), one day before discharge (Z1) and one year after radical surgical treatment (Z2). This main study was followed by a psychometric analysis to measure reliability and to reduce the number of items on the questionnaire. Validity was assessed by medical criteria. The questionnaires presented show a good reliability and validity and can be filled out by patients in less than 20 minutes.

Developments of tumor specific questionnaires for patients with GI tumors according to the guidelines of the EORTC are presented. Results from our prospective and retrospective studies underline the good reliability and satisfactory validity of those GI-modules in combination with the EORTC-QLQ-C-30.

555

PUBLICATION

### Adjuvant intraperitoneal chemotherapy with cisplatin, mitoxantrone, 5-fluorouracil and calcium folinate in stage II-III gastric cancer

E. Topuz<sup>1</sup>, F.N. Aykan<sup>1</sup>, M. Basaran<sup>1</sup>, K. Uygün<sup>1</sup>, F. Tas<sup>1</sup>, B. Sakar<sup>1</sup>, P. Saip<sup>1</sup>, D. Bugra<sup>2</sup>, H. Camlica<sup>1</sup>, A. Aydinler<sup>1</sup>. <sup>1</sup>Oncology Institute, Medical Oncology, Istanbul; <sup>2</sup>Istanbul Medical Faculty, General Surgery, Istanbul, Turkey

Despite numerous trials of postoperative chemotherapy following potentially curative gastric resection, the value of adjuvant therapy is uncertain. Adjuvant chemotherapy is not a standard therapy after complete gastric resection, but there are many trials evaluating the role of adjuvant therapy.

The feasibility, efficacy and toxicity of adjuvant intraperitoneal chemotherapy (IPCT) were evaluated in patients with stage II-III gastric cancer. After complete tumor resection, cisplatin 60 mg/m<sup>2</sup>, mitoxantrone 12 mg/m<sup>2</sup>, 5-fluorouracil 600 mg/m<sup>2</sup> and calcium folinate 60 mg/m<sup>2</sup> were administered in 2 L normal saline intraperitoneally via temporary or semipermanent catheter every 4 weeks for 6 courses to 39 patients and were not removed from the peritoneal cavity. Characteristics of patients were median age 50 (25-66), female 13, male 26, stage II 9 (23%) and stage III 30 (77%).

203 IPCT courses were given. Twenty-seven (69%) patients had received the total of 6 courses. The median number of IPCT courses received per patient was 6 (range 1-6). Toxicity grading was done according to WHO criteria. The toxicity was mild. Non-hematological toxicity included: grade